1. Home
  2. CBAT vs NMRA Comparison

CBAT vs NMRA Comparison

Compare CBAT & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CBAT
  • NMRA
  • Stock Information
  • Founded
  • CBAT 1999
  • NMRA 2019
  • Country
  • CBAT China
  • NMRA United States
  • Employees
  • CBAT N/A
  • NMRA N/A
  • Industry
  • CBAT Industrial Machinery/Components
  • NMRA
  • Sector
  • CBAT Miscellaneous
  • NMRA
  • Exchange
  • CBAT Nasdaq
  • NMRA Nasdaq
  • Market Cap
  • CBAT 104.3M
  • NMRA 121.0M
  • IPO Year
  • CBAT N/A
  • NMRA 2023
  • Fundamental
  • Price
  • CBAT $1.11
  • NMRA $2.00
  • Analyst Decision
  • CBAT
  • NMRA Buy
  • Analyst Count
  • CBAT 0
  • NMRA 8
  • Target Price
  • CBAT N/A
  • NMRA $7.14
  • AVG Volume (30 Days)
  • CBAT 226.5K
  • NMRA 2.1M
  • Earning Date
  • CBAT 08-08-2025
  • NMRA 08-05-2025
  • Dividend Yield
  • CBAT N/A
  • NMRA N/A
  • EPS Growth
  • CBAT N/A
  • NMRA N/A
  • EPS
  • CBAT 0.00
  • NMRA N/A
  • Revenue
  • CBAT $152,731,078.00
  • NMRA N/A
  • Revenue This Year
  • CBAT N/A
  • NMRA N/A
  • Revenue Next Year
  • CBAT $78.62
  • NMRA N/A
  • P/E Ratio
  • CBAT $12,333.33
  • NMRA N/A
  • Revenue Growth
  • CBAT N/A
  • NMRA N/A
  • 52 Week Low
  • CBAT $0.57
  • NMRA $0.61
  • 52 Week High
  • CBAT $1.43
  • NMRA $17.19
  • Technical
  • Relative Strength Index (RSI)
  • CBAT 52.23
  • NMRA 84.53
  • Support Level
  • CBAT $0.92
  • NMRA $0.72
  • Resistance Level
  • CBAT $1.15
  • NMRA $1.41
  • Average True Range (ATR)
  • CBAT 0.07
  • NMRA 0.18
  • MACD
  • CBAT -0.01
  • NMRA 0.09
  • Stochastic Oscillator
  • CBAT 59.38
  • NMRA 96.91

About CBAT CBAK Energy Technology Inc.

CBAK Energy Technology Inc is engaged in the manufacture, commercialization, and distribution of a variety of standard and customized lithium and sodium high-power rechargeable batteries. The batteries are used in light electric vehicles, electric vehicles, energy storage devices, and other high-power applications. The company has two operating segments: CBAK, which derives maximum revenue, and includes the manufacturing, commercialization, and distribution of various standard and customized lithium-ion rechargeable batteries; and the Hitrans segment, which includes the development and manufacturing of NCM precursor and cathode materials. Geographically, the company derives its key revenue from Mainland China, followed by Europe and other regions.

About NMRA Neumora Therapeutics Inc.

Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.

Share on Social Networks: